<DOC>
	<DOCNO>NCT00483600</DOCNO>
	<brief_summary>To determine appropriate dose safety preventative dose fondaparinux , anticoagulant medication ( blood thinner ) patient kidney disease .</brief_summary>
	<brief_title>Pharmacokinetic Study Fondaparinux Outpatients With Renal Dysfunction</brief_title>
	<detailed_description>This study evaluate PK fondaparinux patient renal insufficiency . Fondaparinux clear body mainly kidneys . Therefore patient kidney disease , full dos fondaparinux could cause bleed problem . The correct dose fondaparinux use patient kidney disease know . The purpose research determine PK safety preventative dose ( 2.5mg subcutaneously every day ) fondaparinux patient kidney disease .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Outpatients Medicine Nephrology clinic 18 year old , Outpatients Medicine Nephrology clinic estimate creatinine clearance 2030ml/min , Outpatients Medicine Nephrology clinic able give consent include . anticoagulation therapy thrombosis indication pregnant breastfeeding hypersensitivity fondaparinux subject also exclude concern increase risk bleed include following : know bleed disorder ( see Section 8 . Hemostatic Assessment ) blood transfusion past 3 month acute ulcer disease past 3 month platelet count &lt; 120,000 mm3 prolonged baseline prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) upper limit normal laboratory range major trauma surgery within two week prior enrollment history intracranial hemorrhage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Fondaparinux</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>